Oxford Asset Management’s Trinity Biotech TRIB Stock Holding History

Oxford Asset Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-125	Closed	-$105K	–	1868
2017 Q3	$105K	Buy	125 +38	+44%	+$31.8K	﹤0.01%	1472
2017 Q2	$78K	Sell	87 -211	-71%	-$179K	﹤0.01%	1421
2017 Q1	$266K	Sell	298 -54	-15%	-$50.7K	0.01%	1230
2016 Q4	$365K	Buy	+352	New	+$364K	0.01%	637
2015 Q4	–	Sell	-359	Closed	-$617K	–	948
2015 Q3	$617K	Buy	359 +262	+270%	+$632K	0.02%	475
2015 Q2	$263K	Buy	+97	New	+$252K	0.01%	578

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Oxford Asset Management's TRIB Position: Q4 2017 in Review

Oxford Asset Management sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 125 shares — an estimated $105K sold.

Oxford Asset Management first reported a position in TRIB in Q2 2015 and held it in 6 quarters. The position peaked at $617K in Q3 2015. 47 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

Oxford Asset Management reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
Oxford Asset Management sold 125 Trinity Biotech shares in Q4 2017, an estimated $105K.
Oxford Asset Management first reported a position in Trinity Biotech in Q2 2015 and held it in 6 quarters.
Oxford Asset Management's Trinity Biotech position peaked at $617K in Q3 2015.
47 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Oxford Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.